Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics;Ocena gȩstości mineralnej kości u chorych na schizofreniȩ leczonych lekami przeciwpsychotycznymi II generacji

Psychiatria Polska

Volumn 39, Issue 6, 2005, Pages 1173-1184

  Wyszogrodzka Kucharska, Anna ^a,b   Rabe Jabłońska, Jolanta ^b  

^a Centralny Szpital Kliniczny   (Poland)

^b UM   (Poland)

Author keywords

Bone mineral density; Schizophrenia; Second generation antipsychotics

Indexed keywords

OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; PREMENOPAUSE; SCHIZOPHRENIA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; PREVALENCE; SEX RATIO;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BONE DENSITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; RISPERIDONE; SCHIZOPHRENIA; SEX DISTRIBUTION;

EID: 31044437670     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Baastrup PC, Christiansen C, Transbil I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiol. 1980; 6: 56-59.
2. Ataya K, Merecado A, Kartaginer J, Abbasi A. i in. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. Steril. 1988; 50: 876-881.
3. Abraham G, Friedman RH, Verghese C, de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors? Soc. Biol. Psychiatry 1995; 38: 1171-1172.
4. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 1995; 57: 485-491.
5. Bilici M, Cakirbay H, Guler M, Tosun M. Classical and atypical neuroleptics and bone mineral density in patients with schizophrenia. Int. J. Neurosc. 2002; 112(7): 817-828.
6. Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr. Res. 2003; 59(1): 17-18.
7. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine decreases bone mineral density in female premenopausal schizophrenia patients. J. Clin. Psychiatry 2003; 64(7): 761-766.
8. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, Naveda RC, Rottenbacher M, Fleischhacker WW. Osteoporosis in patients suffering from schizophrenia. [w druku].
9. Climent-Lacroix P, Ormady C, Lepescheux L. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinol. 1999; 140: 96-105.
10. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase on bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 2000; 279(6): 1216-1225.
11. Abraham EJ, Villalobos C, Frawley SL. Effects of cellular interactions on calcium dynamics on prolactin-secreting cells. Endocrinol. 1997; 139(6): 2988-2993.
12. Adler RA, Farrell ME, Dess WP, Krieg RJ, MacLeod RM. Hypercalcuria in a new rat model of hyperprolactinemia. Metabol. 1991; 40(3): 292-296.
13. Kelly EJ, Reiss JP, Drinkwater DT, Faiman C. Bone mineral density, sex hormones, and long-term use of neuroleptics agents in men. Endocrinol. Pract. 1997; 3: 209-213.
14. Arden NK, Spector TD, red. Osteoporoza, aktualny stan wiedzy. Warszawa: Wydawnictwo Medyczne Borgis; 2000.
15. Parhami F. Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor? Prostagland. Leukotr. Essent. Fatty Acids 2003; 68: 373-378.
16. Green AJ, Canuso CM, Brenner MJ, Wójcik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr. Clin. N. Am. 2003; 26, (1): 543-551.
17. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr. Bull. 1996; 3: 447-454.
18. Meaney AM, O Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J. Psychopharmacol. 2003; 17(4): 455-458.